Zelboraf
Zelboraf ingredients
| Active ingredient | Strength |
|---|---|
| Vemurafenib | 240 mg/1 |
What Zelboraf is used for
The FDA lists the approved uses on the official label (below). In the EU, vemurafenib is approved as Zelboraf for:
Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Zelboraf
- Generic name
- Vemurafenib
- Made by
- Genentech, Inc.
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA202429
- On the US market since
- 2011
Official information
- Zelboraf prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Vemurafenib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zelboraf?
Zelboraf (Vemurafenib) is a cancer medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Zelboraf?
Zelboraf contains Vemurafenib (240 mg/1).
Is Zelboraf approved in Europe?
The same active substance is approved in the EU as Zelboraf.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA